Milestones :: Perspectives :: Research
COVID-19 Vaccines – Development Status/Scorecard
321 vaccine candidates against COVID-19 now in development
04 Sep 2020 By CEPI
In April, CEPI researchers identified 115 vaccine candidates against COVID-19 that were at varying stages of development. In an update to this analysis, we report in Nature Reviews Drug Discovery that, in the space of 5 months, this number has nearly tripled to 321 vaccine candidates. 32 of which are now in clinical trials, including eight candidates backed by CEPI.
Global progress in clinical trials and manufacturing
Progress towards a vaccine against COVID-19 has been truly global. Of the 32 candidates that are in clinical trials, there are plans to enroll 280,000 trial participants from at least 470 sites in 34 different countries.
Six clinical candidates are now in the most advanced phase III trials. These include two CEPI-supported candidates (AstraZeneca/Oxford and Moderna) and candidates that are being developed by Gamaleya Research Institute, Wuhan Institute of Biological Products/Sinopharm, Sinovac Biotech, and Pfizer/BioNTech.
For the leading candidates, large-scale manufacturing of vaccines has already been initiated to enable rapid distribution if approval is obtained. For CEPI’s part, it has established manufacturing agreements with AstraZeneca/Oxford, The University of Queensland/CSL, Clover Biopharmaceuticals, Novavax and SK Bioscience.
Technology platforms and vaccine targets
A wide range of technology platforms are being used to develop COVID-19 vaccines, including both traditional and novel approaches.
Early data are emerging for the most advanced clinical candidates and although encouraging antibody and T-cell responses have been reported, it is too early to assess their relative potential…